Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Observational × belzutifan × Clear all

Status

Sponsor Class

Study Type

Interventional 22 Observational 1

Sponsor

Conditions

von Hippel-Lindau Disease 1

Interventions

Blood Specimen Collection 28 Nivolumab 24 Data Collection 24 Sorafenib 23 palbociclib 22 Bevacizumab 22 Observation 19 radium Ra 223 dichloride 18 enzalutamide 17 Sunitinib 17 Rituximab 16 regorafenib 13 Trastuzumab 13 ribociclib 12 exemestane 12 Ipilimumab 12 atezolizumab 11 Leuprolide 11 Drug Therapy 11 Docetaxel 11 apalutamide 10 Standard of Care 10 Capecitabine 10 Bortezomib 10 Afatinib 10 Therapeutics 9 Fulvestrant 9 Cetuximab 9 Anastrozole 9 Abiraterone Acetate 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06554730 2024-11-29

MK-6482-026

Merck Sharp & Dohme LLC

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡